PER
PERCHERON FPO [PER]
Healthcare · ASX Small Cap
$0.0070 +0.0%
Updated 2026-03-02 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Appeared in 2 consecutive scans→ Score -1First seen: 2026-02-25
Score Breakdown
Technical45
Catalyst50
Sentiment50
Fundamental20
Momentum37
Risk Gate35
Active Signals
Bullish Signals
- RSI approaching oversold
- Stochastic oversold
- Sustained volume spike (2.9x median) on DOWN trend
- Near support level (potential bounce)
- Critical cash runway (1.8 quarters)
- 4C filed 2026-01-29
- Low P/S ratio (4.4x)
- Revenue in sharp decline (-42%)
- EPS estimates revised downward (-10pts)
- Near 52-week low (14% of range)
- Micro-cap ($5-20M) - high risk
- Penny stock risk ($0.007)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- Price below MAs (downtrend)
- Below 200-day MA (long-term downtrend)
- Piotroski F-Score weak (3/9)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Negative 12-1 momentum (-27%)
- Revenue momentum declining (-42%)
Recent Catalysts
NONE Half Yearly Report and Accounts
NONE Percheron to Present at the 2026 AACR Annual Meeting
NONE Percheron Therapeutics Limited - Corporate Presentation
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Recent ASX Announcements
| 2026-02-26 | Half Yearly Report and Accounts PRICE SENSITIVE |
| 2026-02-18 | Percheron to Present at the 2026 AACR Annual Meeting |
| 2026-02-17 | Percheron Therapeutics Limited - Corporate Presentation |
| 2026-01-29 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
Key Metrics
$7.6M
Market Cap
711K
Avg Volume
2.9x
Vol Ratio
$0.01 — $0.01
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
-84.6%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 71% |
| L | Leader vs Laggard | laggard | RS: -3 |
| I | Institutional Sponsorship | weak | Inst: 4% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #116 of 119 · Sector avg: 51
View all Healthcare signals →